Interleukin-2 receptor — Drug Target

All drugs that target Interleukin-2 receptor — marketed and clinical-stage. Includes 5 drug classes acting on this target.

Drug classes

CD25-directed Cytotoxin · CD25-directed Cytotoxin [EPC] · Lymphocyte Growth Factor [EPC] · Interleukin-2 Receptor Blocking Antibody · Cytokine

Marketed (6)

• Proleukin · University of Minnesota · Oncology
• Ontak · Eisai · CD25-directed Cytotoxin · Oncology
• Ontak · Eisai · CD25-directed Cytotoxin [EPC] · Oncology
  Ontak works by binding to the interleukin-2 receptor on cancer cells, triggering a toxic response that kills the cells.
• Ontak · The University of Texas Health Science Center at San Antonio · Oncology
• Proleukin · Chiron · Lymphocyte Growth Factor [EPC] · Oncology
• Zenapax · Hoffman-La Roche · Interleukin-2 Receptor Blocking Antibody · Immunology

Phase 3 pipeline (1)

• Zenapax · National Institute of Neurological Disorders and Stroke (NINDS) · Neuroscience

Phase 2 pipeline (2)

• Dose D3 of interleukin-2 · Assistance Publique - Hôpitaux de Paris · Cytokine · Oncology
  Interleukin-2 stimulates T-cell proliferation and activation.
• Dose D1 of interleukin-2 · Assistance Publique - Hôpitaux de Paris · Cytokine · Oncology
  Interleukin-2 stimulates T-cell proliferation and activation.